Latest Treatments of Parkinson's Disease Stories
SAN DIEGO, Feb.
SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
NESS ZIONA, Israel, October 6, 2010 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research.
FORT LEE, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Neurologix, Inc.
NEW YORK, Oct. 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc.
NESS ZIONA, Israel, September 28, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announce today that a platform presentation highlighting the company's new dermal patch for the treatment of Parkinson's disease, ND0611, was given yesterday at the 14th Congress of the European Federation of Neurological Societies in Geneva, Switzerland.
RICHMOND, Calif., July 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has been awarded a second round of funding by The Michael J.
NEW YORK, July 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded research teams at eight biotech and pharmaceutical companies a total of $3 million for pre-clinical Parkinson's drug development projects.
FORT LEE, N.J., June 22 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease (PD), NLX-P101.
NESS ZIONA, Israel, June 1, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611.